Female (N, %)
|
66 (97.1%)
| |
Age (years)
|
31.7 ± 10.0
|
32 (23, 38)
|
Body weight (kg)
|
54.7 ± 14.9
|
50.9 (45.9, 62)
|
Body mass index
|
20.1 ± 3.9
| |
Duration of SLE (years)
|
6.3 ± 6.3
|
4 (2, 8.5)
|
Systolic blood pressure (mmHg)
|
126.7 ± 24.3
|
128 (119, 138.5)
|
Diastolic blood pressure (mmHg)
|
79.4 ± 19.2
|
78.5 (70, 92)
|
Systemic organ involvements (N, %)
|
Arthritis
|
14 (20.6%)
| |
Cutaneous lupus
|
14 (20.6%)
| |
Hematologic involvement
|
8 (11.8%)
| |
Serositis
|
4 (5.9%)
| |
Neurological involvement
|
1 (1.5%)
| |
Baseline SLEDAI score
|
10.8 ± 3.3
|
10 (8, 12)
|
Baseline Renal SLEDAI score
|
7.0 ± 2.9
|
8 (4, 8)
|
ISN/RPS class (N, %)
|
Class III
|
5 (7.4%)
| |
Class IV
|
49 (72.1%)
| |
Class III + V
|
4 (5.9%)
| |
Class IV + V
|
10 (14.7%)
| |
Renal activity index
|
8.5 ± 2.9
|
8 (6, 11.5)
|
Renal chronicity index
|
1.9 ± 1.7
|
2 (0, 3)
|
Immunosuppressive agents (N, %)
|
Induction with high cyclophosphamide
|
37 (62.7%)
| |
Induction with mycophenolate
|
22 (37.3%)
| |
Mean dose of mycophenolate (mg/day)
|
29.6 ± 17.1
|
30 (20, 35)
|
Prednisolone
|
67 (98.5%)
| |
Hydroxychloroquine
|
32 (47.1%)
| |
Anti-hypertensive and lipid lowering agents (N, %)
|
RAAS blockers
|
51 (75%)
| |
Calcium channel blockers
|
10 (14.7%)
| |
Diuretics
|
28 (41.2%)
| |
Statins
|
43 (63.2%)
| |
Laboratory data
|
Positive ANA (%)
|
67 (98.5%)
| |
Positive anti-dsDNA (%)
|
57 (83.8%)
| |
Low complement component 3 (C3) (%)
|
31 (60.8%)
| |
Serum complement component C3 levels (g/L)
|
1.2 ± 1.8
|
0.7 (0.4, 1.1)
|
Hematocrit (%)
|
26.5 ± 11.2
|
30 (13.7, 34.6)
|
Serum albumin (g/dL)
|
2.7 ± 0.9
|
3 (2, 3.2)
|
Serum creatinine (mg/dL)
|
0.9 ± 0.5
|
0.8 (0.7, 1.1)
|
Estimated GFR (mL/min/1.73 m2)
|
89.6 ± 33.7
|
89.4 (63.7, 116.8)
|
UPCR (g/g creatinine)
|
5.9 ± 4.8
|
4.8 (2.5, 6.9)
|